TuisALC • NYSE
add
Alcon AG
Vorige sluiting
$86,93
Dagwisseling
$86,79 - $88,06
Jaarwisseling
$80,48 - $101,10
Markkapitalisasie
36,45 mjd CHF
Gemiddelde volume
1,64 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
SWX
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 2,47 mjd | 0,57% |
Bedryfskoste | 1,05 mjd | 3,94% |
Netto inkomste | 350,00 m | 41,13% |
Netto winsgrens | 14,15 | 40,24% |
Wins per aandeel | 0,73 | -6,41% |
EBITDA | 476,00 m | -26,09% |
Effektiewe belastingkoers | 15,46% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,41 mjd | 23,10% |
Totale bates | 31,01 mjd | 4,88% |
Totale aanspreeklikheid | 8,99 mjd | 2,87% |
Totale ekwiteit | 22,02 mjd | — |
Uitstaande aandele | 495,70 m | — |
Prys om te bespreek | 1,96 | — |
Opbrengs op bates | 2,68% | — |
Opbrengs op kapitaal | 3,05% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 350,00 m | 41,13% |
Kontant van bedrywe | 384,00 m | 12,61% |
Kontant van beleggings | -578,00 m | -165,14% |
Kontant van finansiering | -96,00 m | -45,45% |
Netto kontantverandering | -264,00 m | -661,70% |
Beskikbare kontantvloei | 17,00 m | -90,85% |
Meer oor
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
Gestig
1945
Hoofkwartier
Webwerf
Werknemers
25 000
